A pharma giant is moving past one patent cliff — but another is already looming
CNBC Markets · Fri, 30 Oct 2026 06:00:01 GMT
Read the full story at CNBC Markets ↗OmniFin Portal's take
Excerpt from CNBC Markets: “Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.”
Rule-based headline sentiment: Neutral
More Stocks headlines
Has the tech bubble burst? Why the Nasdaq’s rough ride looks eerily like 2000.— MarketWatchAlaska Senate election: DOJ wants to 'segregate' all ballots for 2nd Sullivan candidate— CNBC MarketsJim Cramer says it's time to look beyond tech. Here are 4 consumer stocks he likes— CNBC MarketsMeta outlook revised downward by S&P on cash flow and capex concerns— CNBC Markets
New to the fundamentals behind stories like this?
OmniFin Academy covers money basics, risk management, and reading markets — free, self-paced, no sign-up required.
Start OmniFin Academy →